{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:27:05Z","timestamp":1786987625372,"version":"build-2736575974"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ctrv.2024.102785","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T02:26:15Z","timestamp":1718072775000},"page":"102785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Prevention, diagnosis and clinical management of hereditary breast cancer beyond BRCA1\/2 genes"],"prefix":"10.1016","volume":"129","author":[{"given":"A.","family":"Calabrese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"von Arx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Tafuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pensabene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"De Laurentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2024.102785_b0005","doi-asserted-by":"crossref","unstructured":"Winters S, Martin C, Murphy D, Shokar NK. Breast Cancer Epidemiology, Prevention, and Screening. In 2017. p. 1\u201332.","DOI":"10.1016\/bs.pmbts.2017.07.002"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102785_b0010","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s12282-020-01148-2","article-title":"Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis","volume":"28","author":"Yoshida","year":"2021","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ctrv.2024.102785_b0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.breast.2022.10.014","article-title":"PARP-inhibitors for BRCA1\/2-related advanced HER2-negative breast cancer: a meta-analysis and GRADE recommendations by the Italian association of medical oncology","volume":"66","author":"Miglietta","year":"2022","journal-title":"Breast"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102785_b0020","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102785_b0025","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.ctrv.2024.102785_b0030","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1 - or BRCA2 -mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102785_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100235","article-title":"Impact of deleterious variants in other genes beyond BRCA1\/2 detected in breast\/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge","volume":"6","author":"Bono","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2024.102785_b0040","unstructured":"Dwyer, Mary. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines \u00ae) Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic [Internet]. 2024. Available from: https:\/\/www.nccn.org\/home\/member-."},{"issue":"1","key":"10.1016\/j.ctrv.2024.102785_b0045","doi-asserted-by":"crossref","first-page":"14737","DOI":"10.1038\/s41598-021-94316-z","article-title":"Sequencing for germline mutations in Swedish breast cancer families reveals novel breast cancer risk genes","volume":"11","author":"Helgadottir","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102785_b0050","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/cam4.4541","article-title":"Racial and ethnic variation in multigene panel testing in a cohort of BRCA1\/2 -negative individuals who had genetic testing in a large urban comprehensive cancer center","volume":"11","author":"Tatineni","year":"2022","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102785_b0055","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1002\/ijc.31921","article-title":"Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing","volume":"144","author":"Girard","year":"2019","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102785_b0060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10689-017-0004-z","article-title":"A multi-gene panel study in hereditary breast and ovarian cancer in Colombia","volume":"17","author":"Cock-Rada","year":"2018","journal-title":"Fam Cancer"},{"key":"10.1016\/j.ctrv.2024.102785_b0065","first-page":"14","article-title":"Multi-gene panel testing and association analysis in Cypriot breast cancer cases and controls","volume":"18","author":"Zanti","year":"2023","journal-title":"Front Genet"},{"issue":"55","key":"10.1016\/j.ctrv.2024.102785_b0070","doi-asserted-by":"crossref","first-page":"30649","DOI":"10.18632\/oncotarget.25769","article-title":"Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers","volume":"9","author":"Chan","year":"2018","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102785_b0075","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s00432-018-2763-9","article-title":"Multigene panel testing beyond BRCA1\/2 in breast\/ovarian cancer Spanish families and clinical actionability of findings","volume":"144","author":"Bonache","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102785_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100947","article-title":"The landscape of reported VUS in multi-gene panel and genomic testing: Time for a change","volume":"25","author":"Rehm","year":"2023","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102785_b0085","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3390\/genes12050616","article-title":"Clinicopathologic profile of breast cancer in germline ATM and CHEK2 mutation carriers","volume":"12","author":"Toss","year":"2021","journal-title":"Genes (Basel)"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102785_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2021.104350","article-title":"Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe","volume":"64","author":"Marmolejo","year":"2021","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.ctrv.2024.102785_b0095","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.aca.2018.09.032","article-title":"A multi-gene panel beyond BRCA1\/BRCA2 to identify new breast cancer-predisposing mutations by a picodroplet PCR followed by a next-generation sequencing strategy: a pilot study","volume":"1046","author":"Nunziato","year":"2019","journal-title":"Anal Chim Acta"},{"key":"10.1016\/j.ctrv.2024.102785_b0100","first-page":"9","article-title":"Multi-gene panel testing increases germline predisposing mutations\u2019 detection in a cohort of breast\/ovarian cancer patients from Southern Italy","volume":"11","author":"Nunziato","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102785_b0105","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102785_b0110","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10549-017-4531-y","article-title":"Clinical implications of germline mutations in breast cancer: TP53","volume":"167","author":"Schon","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2024.102785_b0115","unstructured":"Chen YL WCFJHH. Serine\/threonine-protein kinase 24 is an inhibitor of gastric cancer metastasis through suppressing CDH1 gene and enhancing stemness."},{"issue":"1","key":"10.1016\/j.ctrv.2024.102785_b0120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13058-015-0546-7","article-title":"Lobular breast cancer: incidence and genetic and non-genetic risk factors","volume":"17","author":"Dossus","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102785_b0125","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/j.gastro.2023.01.038","article-title":"Hereditary Diffuse Gastric Cancer","volume":"164","author":"Decourtye-Espiard","year":"2023","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102785_b0130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13058-022-01574-4","article-title":"Androgen receptor function and targeted therapeutics across breast cancer subtypes","volume":"24","author":"Kolyvas","year":"2022","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102785_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-015-3665-z","article-title":"Breast cancer risk and clinical implications for germline PTEN mutation carriers","volume":"165","author":"Ngeow","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102785_b0140","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/hmg\/ddz027","article-title":"Novel germline STK11 variants and breast cancer phenotype identified in an Indian cohort of Peutz-Jeghers syndrome","volume":"28","author":"Lipsa","year":"2019","journal-title":"Hum Mol Genet"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102785_b0145","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/jmg-2023-109464","article-title":"CHEK2 is not a Li-Fraumeni syndrome gene: time to update public resources","volume":"60","author":"Fortuno","year":"2023","journal-title":"J Med Genet"},{"key":"10.1016\/j.ctrv.2024.102785_b0150","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1200\/PO.19.00178","article-title":"Pathogenic variants in CHEK2 are associated with an adverse prognosis in symptomatic early-onset breast cancer","volume":"4","author":"Greville-Heygate","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102785_b0155","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1002\/humu.24110","article-title":"Comprehensive analysis and ACMG-based classification of CHEK2 variants in hereditary cancer patients","volume":"41","author":"Vargas-Parra","year":"2020","journal-title":"Hum Mutat"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102785_b0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s42003-021-02990-6","article-title":"Rare germline copy number variants (CNVs) and breast cancer risk","volume":"5","author":"Dennis","year":"2022","journal-title":"Commun Biol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102785_b0165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12885-020-07749-6","article-title":"The association between ATM variants and risk of breast cancer: a systematic review and meta-analysis","volume":"21","author":"Moslemi","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2024.102785_b0170","first-page":"531","article-title":"Increased risk of breast cancer in neurofibromatosis type 1: current insights","volume":"9","author":"Howell","year":"2017","journal-title":"Breast Cancer: Targets and Therapy"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102785_b0175","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/jmg-2022-108898","article-title":"UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2","volume":"60","author":"Hanson","year":"2023","journal-title":"J Med Genet"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102785_b0180","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/path.5422","article-title":"Molecular pathology of lynch syndrome","volume":"250","author":"Cerretelli","year":"2020","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102785_b0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/jnci\/djp473","article-title":"Risks of lynch syndrome cancers for MSH6 mutation carriers","volume":"102","author":"Baglietto","year":"2010","journal-title":"JNCI: J Nat Cancer Inst"},{"key":"10.1016\/j.ctrv.2024.102785_b0190","first-page":"10","article-title":"Lynch syndrome germline mutations in breast cancer: next generation sequencing case-control study of 1,263 participants","volume":"29","author":"Nikitin","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102785_b0195","doi-asserted-by":"crossref","first-page":"106","DOI":"10.5152\/ejbh.2020.5198","article-title":"Investigating the link between lynch syndrome and breast cancer","volume":"16","author":"Sheehan","year":"2020","journal-title":"Eur J Breast Health"},{"issue":"40","key":"10.1016\/j.ctrv.2024.102785_b0200","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1038\/s41388-021-01984-2","article-title":"POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes","volume":"40","author":"Magrin","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2024.102785_b0205","unstructured":"Bookshelf_NBK107219."},{"issue":"6","key":"10.1016\/j.ctrv.2024.102785_b0210","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1016\/j.clbc.2021.04.002","article-title":"Clinical contribution of next-generation sequencing multigene panel testing for BRCA negative high-risk patients with breast cancer","volume":"21","author":"Ece Solmaz","year":"2021","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102785_b0215","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10689-018-00114-4","article-title":"Monoallelic MUTYH carrier status is not associated with increased breast cancer risk in a multigene panel cohort","volume":"18","author":"Fulk","year":"2019","journal-title":"Fam Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102785_b0220","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10549-023-07173-x","article-title":"Breast cancers in monoallelic MUTYH germline mutation carriers have clinicopathological features overlapping with those in BRCA1 germline mutation carriers","volume":"204","author":"Keske","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102785_b0225","doi-asserted-by":"crossref","first-page":"428","DOI":"10.5306\/wjco.v11.i7.428","article-title":"MUTYH: not just polyposis","volume":"11","author":"Curia","year":"2020","journal-title":"World J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102785_b0230","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3390\/cancers12040829","article-title":"Exploring the role of mutations in fanconi anemia genes in hereditary cancer patients","volume":"12","author":"del Valle","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102785_b0235","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41431-022-01257-w","article-title":"FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women","volume":"31","author":"Figlioli","year":"2023","journal-title":"Eur J Hum Genet"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102785_b0240","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3390\/genes11080856","article-title":"Literature review of BARD1 as a cancer predisposing gene with a focus on breast and ovarian cancers","volume":"11","author":"Alenezi","year":"2020","journal-title":"Genes (Basel)"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102785_b0245","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.3390\/ijms22115832","article-title":"Detecting variants in the NBN gene while testing for hereditary breast cancer: what to do next?","volume":"22","author":"Zuntini","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102785_b0250","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ogc.2021.11.009","article-title":"Breast cancer risk assessment and management of the high-risk patient","volume":"49","author":"Green","year":"2022","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102785_b0255","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1001\/jamasurg.2020.6254","article-title":"American society of clinical oncology, american society for radiation oncology, and society of surgical oncology guideline for management of hereditary breast cancer","volume":"156","author":"Yip","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ctrv.2024.102785_b0260","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.breast.2019.10.012","article-title":"Breast cancer surveillance for BRCA1\/2 mutation carriers \u2013 is \u201cearly detection\u201d early enough?","volume":"49","author":"Bernstein-Molho","year":"2020","journal-title":"Breast"},{"issue":"04","key":"10.1016\/j.ctrv.2024.102785_b0265","doi-asserted-by":"crossref","first-page":"e7160","DOI":"10.5867\/medwave.2018.04.7160","article-title":"Prophylactic mastectomy versus surveillance for the prevention of breast cancer in women\u2019s BRCA carriers","volume":"18","author":"Honold","year":"2018","journal-title":"Medwave"},{"issue":"30","key":"10.1016\/j.ctrv.2024.102785_b0270","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1200\/JCO.2004.00.7138","article-title":"Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study","volume":"23","author":"Eisen","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102785_b0275","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1245\/s10434-015-4715-9","article-title":"Chemoprevention for Breast Cancer","volume":"22","author":"Pruthi","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2024.102785_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102702","article-title":"Cancer genetic counselling for hereditary breast cancer in the era of precision oncology","volume":"125","author":"Pensabene","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102785_b0285","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","article-title":"Guidelines for the Li\u2013Fraumeni and heritable TP53-related cancer syndromes","volume":"28","author":"Frebourg","year":"2020","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102785_b0290","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.3390\/cancers12061598","article-title":"Hereditary gastric and breast cancer syndromes related to CDH1 germline mutation: a multidisciplinary clinical review","volume":"12","author":"Corso","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102785_b0295","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s41436-021-01151-8","article-title":"Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Tischkowitz","year":"2021","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102785_b0300","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamaoncol.2021.6204","article-title":"Breast cancer screening strategies for women with ATM, CHEK2, and PALB2 pathogenic variants","volume":"8","author":"Lowry","year":"2022","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102785_b0305","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3390\/cancers11050707","article-title":"NF1 patients receiving breast cancer screening: insights from the ontario high risk breast screening program","volume":"11","author":"Maani","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102785_b0310","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10549-021-06410-5","article-title":"Uptake and timing of bilateral and contralateral risk-reducing mastectomy in women with Li\u2013Fraumeni syndrome","volume":"191","author":"Siegel","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102785_b0315","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/CEJ.0000000000000688","article-title":"CDH1 germline mutations in families with hereditary lobular breast cancer","volume":"31","author":"Girardi","year":"2022","journal-title":"Eur J Cancer Prev"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102785_b0320","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000525146","article-title":"The complex management of the breast angiosarcoma: a retrospective study","volume":"101","author":"Cannella","year":"2023","journal-title":"Oncology"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102785_b0325","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/jnci\/djaa023","article-title":"The Contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort","volume":"112","author":"Hu","year":"2020","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102785_b0330","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.ygeno.2021.04.029","article-title":"Germline and somatic mutation profile in cancer patients revealed by a medium-sized pan-Cancer panel","volume":"113","author":"Li","year":"2021","journal-title":"Genomics"},{"issue":"36","key":"10.1016\/j.ctrv.2024.102785_b0335","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102785_b0340","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","article-title":"DNA Damage and repair biomarkers of immunotherapy response","volume":"7","author":"Mouw","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2024.102785_b0345","doi-asserted-by":"crossref","unstructured":"Michel B, Flores MJ, Viguera E, Grompone G, Seigneur M, Bidnenko V. Rescue of arrested replication forks by homologous recombination. Proceedings of the National Academy of Sciences. 2001 Jul 17;98(15):8181\u20138.","DOI":"10.1073\/pnas.111008798"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102785_b0350","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s43018-022-00439-1","article-title":"A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes","volume":"3","author":"Gruber","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ctrv.2024.102785_b0355","unstructured":"Yap TA, Schram AM, Balma\u00f1a J, et al. PETRA: first-in-human phase 1\/2a trial of the first-in-class new generation poly(ADP-ribose) polymerase-1 selective inhibitor (PARP1i) saruparib (AZD5305) in patients with advanced solid tumors with BRCA1\/2, PALB2 or RAD51C\/D mutations. Presented at the American Association for Cancer Research (AACR) 2024 Annual Meeting; April 5-10, 2024; San Diego, CA. Abstract CT014."},{"issue":"11","key":"10.1016\/j.ctrv.2024.102785_b0360","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","article-title":"Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study","volume":"26","author":"Abida","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.ctrv.2024.102785_b0365","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II study of maintenance rucaparib in patients With platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102785_b0370","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (1979). 2017 Jul 28;357(6349):409\u201313."},{"issue":"18","key":"10.1016\/j.ctrv.2024.102785_b0375","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1158\/0008-5472.CAN-17-1083","article-title":"Whole-genome sequencing reveals breast cancers with mismatch repair deficiency","volume":"77","author":"Davies","year":"2017","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102785_b0380","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1078-0432.CCR-21-2027","article-title":"Morphologic and genomic characteristics of breast cancers occurring in individuals with lynch syndrome","volume":"28","author":"Schwartz","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102785_b0385","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41523-022-00417-x","article-title":"Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients","volume":"8","author":"Hu","year":"2022","journal-title":"npj Breast Cancer"},{"issue":"13","key":"10.1016\/j.ctrv.2024.102785_b0390","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102785_b0395","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/humu.21158","article-title":"MUTYH mutations associated with familial adenomatous polyposis: functional characterization by a mammalian cell-based assay","volume":"31","author":"Molatore","year":"2010","journal-title":"Hum Mutat"},{"issue":"19","key":"10.1016\/j.ctrv.2024.102785_b0400","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1101\/gad.1688508","article-title":"Genomic predictors of interindividual differences in response to DNA damaging agents","volume":"22","author":"Fry","year":"2008","journal-title":"Genes Dev"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102785_b0405","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/sj.emboj.7601975","article-title":"Two distinct pathways of cell death triggered by oxidative damage to nuclear and mitochondrial DNAs","volume":"27","author":"Oka","year":"2008","journal-title":"EMBO J"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102785_b0410","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/ejhg.2014.15","article-title":"Biallelic MUTYH mutations can mimic Lynch syndrome","volume":"22","author":"Morak","year":"2014","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102785_b0415","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1471-2407-9-184","article-title":"Colorectal carcinomas in MUTYH-associated polyposis display histopathological similarities to microsatellite unstable carcinomas","volume":"9","author":"Nielsen","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2024.102785_b0420","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.breast.2022.06.003","article-title":"Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D","volume":"65","author":"Graffeo","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2024.102785_b0425","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.02225","article-title":"Germline testing in patients with breast cancer: ASCO\u2013society of surgical oncology guideline","author":"Bedrosian","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T19:59:06Z","timestamp":1723665546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224001130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":85,"alternative-id":["S0305737224001130"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102785","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention, diagnosis and clinical management of hereditary breast cancer beyond BRCA1\/2 genes","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102785","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102785"}}